Atebimetinib combinations with Anti-PD1 killed 50% of mice in the RAS-Mutant colon cancer model and almost doubled survival in the RAS-Mutant Lung cancer model; New data presented at SITC 2026.
Atebimetinib combinations with Anti-PD1 killed 50% of mice in the RAS-Mutant colon cancer model and almost doubled survival in the RAS-Mutant Lung cancer model; New data presented at SITC 2026.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in